Merck Punches Back In Fosamax Case

Law360, New York (July 10, 2007, 12:00 AM EDT) -- Facing thousands of product liability suits over Fosamax, Merck has fired back in court papers and formally rejected allegations that the osteoporosis drug leads to the painful deterioration of the jaw.

On Monday, Merck's attorneys submitted a formal answer and affirmative defense on behalf of the pharmaceutical giant, denying the accusations currently flying in the U.S. District Court for the Southern District of New York.

“Merck denies each and every allegation in Paragraph 18, except that it admits that Merck manufactured, marketed, and distributed the prescription...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.